Phase III results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj. Multi-dose, demonstrate that it ...

The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...

Changchung Genescience Pharmaceutical Co. Ltd., reported effects of the bispecific antibody-drug conjugate (ADC) of ...

The vaccine effectiveness of PCV20 against IPD and all-cause pneumonia was highest among individuals aged 65 to 74 years and decreased with increasing age.

A251, a novel HER2 antibody-drug conjugate (ADC) designed to deliver a potent PI3K/PIKK inhibitor directly to tumor cells.

PATH and EuBiologics Co., LTD are pleased to announce Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj. ® Multi-dose is manufactured ...

Antibodies serve as foundational tools across a broad range of research fields from immunology to oncology and infectious ...

Merck has entered a definitive agreement to acquire Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate ...

Merck and Cidara Therapeutics, Inc., have entered into a definitive agreement under which Merck will acquire Cidara for $9.2 ...

Antibody-drug conjugates (ADCs) are transforming oncology by combining the precision of monoclonal antibodies with the potency of cytotoxic drugs. Yet, developing effective ADCs requires overcoming ...